[go: up one dir, main page]

MX2009008135A - Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas. - Google Patents

Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.

Info

Publication number
MX2009008135A
MX2009008135A MX2009008135A MX2009008135A MX2009008135A MX 2009008135 A MX2009008135 A MX 2009008135A MX 2009008135 A MX2009008135 A MX 2009008135A MX 2009008135 A MX2009008135 A MX 2009008135A MX 2009008135 A MX2009008135 A MX 2009008135A
Authority
MX
Mexico
Prior art keywords
treatment
chromium histidinate
chromium
cardiometabolic disorders
cardiometabolic
Prior art date
Application number
MX2009008135A
Other languages
English (en)
Inventor
James Komorowski
Vijaya Juturu
Original Assignee
Nutrition 21 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 Inc filed Critical Nutrition 21 Inc
Publication of MX2009008135A publication Critical patent/MX2009008135A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona en la presente métodos para el tratamiento, prevención y mejora de condiciones asociadas con síndrome cardiometabólico al identificar un sujeto en necesidad de tratamiento, prevención o mejora de una condición asociada con síndrome cardiometabólico y proveer una cantidad terapéuticamente efectiva de una composición que comprende cromo e histidina, complejo de histidinato de cromo o combinaciones de los mismos al individuo.
MX2009008135A 2007-01-31 2008-01-29 Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas. MX2009008135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88756107P 2007-01-31 2007-01-31
PCT/US2008/052352 WO2008094939A1 (en) 2007-01-31 2008-01-29 Use of chromium histidinate for treatment of cardiometabolic disorders

Publications (1)

Publication Number Publication Date
MX2009008135A true MX2009008135A (es) 2009-08-12

Family

ID=39674481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008135A MX2009008135A (es) 2007-01-31 2008-01-29 Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.

Country Status (6)

Country Link
US (4) US20100009015A1 (es)
EP (1) EP2120930A4 (es)
AU (1) AU2008210586B2 (es)
CA (3) CA2676977C (es)
MX (1) MX2009008135A (es)
WO (1) WO2008094939A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3050568T3 (pl) 2007-03-13 2021-06-14 Jds Therapeutics, Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
PL2448412T3 (pl) * 2009-07-01 2019-11-29 Jds Therapeutics Llc Kompleksy chromu jako środki podnoszące poziom transporterów glukozy w mózgu
CN105749253A (zh) 2011-03-01 2016-07-13 Jds治疗有限公司 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物
US20130110531A1 (en) * 2011-10-29 2013-05-02 Kenneth O Russell Method for reducing healthcare costs
GB2587289B (en) * 2015-06-23 2021-06-23 Jds Therapeutics Llc Chromium Histidinate Complexes
CN109069532A (zh) 2016-02-11 2018-12-21 营养21有限责任公司 含铬组合物用于改善健康和健身
WO2018031425A1 (en) * 2016-08-08 2018-02-15 Glucare, Llc Pharmaceutical compositions comprising chromium and carbohydrate blockers
EP3716962A1 (en) 2017-12-01 2020-10-07 INSERM - Institut National de la Santé et de la Recherche Médicale Use of triethylenetetramine (teta) for the therapeutic induction of autophagy
WO2019238934A1 (en) 2018-06-15 2019-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the apolipoprotein m for the treatment and diagnosis of insulin resistance
WO2020172262A1 (en) * 2019-02-19 2020-08-27 James Janine Chromium composition and methods thereof
EP4309733A1 (en) 2022-07-22 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Neutralization of acyl-coa binding protein for the treatment of cardiac dysfunction

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0016496B1 (en) * 1979-03-19 1983-10-19 THE PROCTER & GAMBLE COMPANY Chromium acetylacetonate as a dietary supplement and pharmaceutical agent
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
USRE33988E (en) * 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US4954492A (en) * 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5175156A (en) * 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
US5087624A (en) * 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5614553A (en) * 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5336672A (en) * 1992-07-21 1994-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Increasing egg production in poultry
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US6329361B1 (en) * 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
US5635535A (en) * 1996-04-05 1997-06-03 Wagstaff; Robert K. Method for increasing blood glucose levels
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
AU751431B2 (en) * 1997-08-08 2002-08-15 Nutrition 21 Chromium/biotin treatment of type II diabetes
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US6689383B1 (en) * 1999-10-08 2004-02-10 The United States Of America As Represented By The Secretary Of Agriculture Chromium-histidine complexes as nutrient supplements
EP1357977B1 (en) * 2000-09-21 2004-07-21 Nutrition 21, Inc. Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
US20020098247A1 (en) * 2000-11-02 2002-07-25 Komorowski James R. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
ATE339961T1 (de) * 2001-02-27 2006-10-15 Nutrition 21 Inc Chromium/biotin behandlung von dyslipidemia
CA2480268A1 (en) * 2002-04-23 2003-11-06 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
US7063865B2 (en) * 2002-05-10 2006-06-20 Jeremy Park Jones Composition and method for substantially reducing the deleterious effects of alcohol on the body
US20040005368A1 (en) * 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US20050069593A1 (en) * 2003-09-29 2005-03-31 Life Time Fitness, Inc. Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
US20060024383A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses
PL3050568T3 (pl) * 2007-03-13 2021-06-14 Jds Therapeutics, Llc Sposoby i kompozycje do przedłużonego uwalniania chromu

Also Published As

Publication number Publication date
WO2008094939A1 (en) 2008-08-07
EP2120930A4 (en) 2012-12-05
CA3021932C (en) 2020-12-15
US20220023337A1 (en) 2022-01-27
CA2931881A1 (en) 2008-08-07
EP2120930A1 (en) 2009-11-25
CA3021932A1 (en) 2008-08-07
CA2676977A1 (en) 2008-08-07
CA2676977C (en) 2016-10-04
AU2008210586A1 (en) 2008-08-07
US20100009015A1 (en) 2010-01-14
US20150272991A1 (en) 2015-10-01
AU2008210586B2 (en) 2013-07-04
CA2931881C (en) 2018-12-11
US20130101681A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MY172372A (en) Compositions and methods for lowering triglycerides
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MX2010006823A (es) Metodos para el tratamiento de la gota.
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008153730A3 (en) Method for treating proliferative disorders associated with mutations in c-met
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
MX2009010132A (es) Analogos de pirazolopirimidina y su uso como inhibidores de cinasa mtor y cinasa pi3.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
HK1214552A1 (zh) 在腎損傷的受試者中用泊馬度胺治療癌症
WO2007144057A3 (en) Antimicrobial carbon
IN2012DN01414A (es)
IN2012DN02195A (es)
WO2008090209A3 (en) Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders
MX2009009693A (es) Metodos para activar irs-1 y akt.
IN2012DN00549A (es)

Legal Events

Date Code Title Description
FG Grant or registration